Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone · Investor's Business Daily

In This Article:

Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.